Streetbeat News

MDAI

Spectral AI, Inc.

Industry

Medical - Devices

Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.

Open

1.90

Mkt cap

38M

Volume

5.2M

High

2.04

P/E Ratio

-2.95

52-wk high

3.72

Low

1.78

Div yield

N/A

52-wk low

0.82

Spectral AI (NASDAQ: MDAI) has completed the truthing of burn center images, a key step in training its DeepView® System for wound healing predictions. The company is now expanding this process to emergency department images.

Portfolio Pulse from

December 02, 2024 | 2:00 pm

Spectral AI has announced the repricing of its public warrants, reducing the exercise price from $11.50 to $2.75 per share. This change is aimed at making the warrants more attractive to investors.

Portfolio Pulse from

November 26, 2024 | 3:30 pm

Spectral AI, Inc. (Nasdaq: MDAI) has raised approximately $5 million through an equity financing to strengthen its financial position. The funds will help retire obligations and support the FDA submission of its DeepView AI®-Burn system, expected in the first half of 2025.

Portfolio Pulse from

November 19, 2024 | 1:15 pm

Spectral AI, Inc. (NASDAQ:MDAI) held its Q3 2024 earnings conference call, discussing financial results and company performance.

Portfolio Pulse from

November 09, 2024 | 7:30 pm

Spectral AI Inc (NASDAQ:MDAI) reported a strong Q3 2024 performance with a 138% increase in R&D revenue, reaching $8.2 million, up from $3.4 million in Q3 2023. The company is advancing its burn wound technology and reaffirmed its FDA submission timeline.

Portfolio Pulse from

November 06, 2024 | 9:45 pm

Spectral AI reported its 2024 third quarter financial results, with revenue rising to $8.2 million. The company also reaffirmed its timeline for regulatory submission to the U.S. FDA.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

Spectral AI Inc (NASDAQ:MDAI) plans to spin off its subsidiary, Spectral IP, Inc., to focus on IP monetization and healthcare AI expansion. The deal with Sauvegarder Investment Management, Inc. aims to position Spectral IP as an independent company targeting various sectors.

Portfolio Pulse from

November 06, 2024 | 2:15 pm

Spectral AI plans to spin off its Spectral IP subsidiary to focus on intellectual property investments and monetization. This strategic move aims to unlock IP value and sharpen the company's focus on AI medical diagnostics.

Portfolio Pulse from

November 06, 2024 | 1:15 pm

Spectral AI, Inc. (NASDAQ:MDAI) has completed its U.S. Burn Pivotal Study, a major step towards FDA submission for its DeepView AI-Burn system in 2025. This system aims to improve burn wound diagnostics.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:14 pm

Spectral AI's CEO, Peter Carlson, has resigned, and the company has established an Office of the Chairman, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.